PL2060569T3 - Hemihydrat metanosulfonianu estru etylowego kwasu 3-[(2-{[4-heksylokarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionowego i jego zastosowanie jako leku - Google Patents

Hemihydrat metanosulfonianu estru etylowego kwasu 3-[(2-{[4-heksylokarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionowego i jego zastosowanie jako leku

Info

Publication number
PL2060569T3
PL2060569T3 PL09153155T PL09153155T PL2060569T3 PL 2060569 T3 PL2060569 T3 PL 2060569T3 PL 09153155 T PL09153155 T PL 09153155T PL 09153155 T PL09153155 T PL 09153155T PL 2060569 T3 PL2060569 T3 PL 2060569T3
Authority
PL
Poland
Prior art keywords
methyl
hexyloxycarbonylamino
benzimidazol
phenylamino
imino
Prior art date
Application number
PL09153155T
Other languages
English (en)
Polish (pl)
Inventor
Peter Sieger
Rainer Sobotta
Rolf Schmid
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34202202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2060569(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PL2060569T3 publication Critical patent/PL2060569T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL09153155T 2003-08-29 2004-08-24 Hemihydrat metanosulfonianu estru etylowego kwasu 3-[(2-{[4-heksylokarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionowego i jego zastosowanie jako leku PL2060569T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10339862A DE10339862A1 (de) 2003-08-29 2003-08-29 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP04764411A EP1660482B1 (fr) 2003-08-29 2004-08-24 Ethylester-methansulfonate d'acide 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methil-1h - -benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionique et son utilisation en tant que medicament
EP09153155A EP2060569B1 (fr) 2003-08-29 2004-08-24 Hemihydrate de méthanesulfonate d'éthylester d'acide 3-[(2-{[4-hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionique et son utilisation comme médicament

Publications (1)

Publication Number Publication Date
PL2060569T3 true PL2060569T3 (pl) 2012-03-30

Family

ID=34202202

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09153155T PL2060569T3 (pl) 2003-08-29 2004-08-24 Hemihydrat metanosulfonianu estru etylowego kwasu 3-[(2-{[4-heksylokarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionowego i jego zastosowanie jako leku
PL04764411T PL1660482T3 (pl) 2003-08-29 2004-08-24 Metanosulfonian 3-[(2-{[4-(heksyloksykarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionianu etylu i jego zastosowanie jako leku

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04764411T PL1660482T3 (pl) 2003-08-29 2004-08-24 Metanosulfonian 3-[(2-{[4-(heksyloksykarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionianu etylu i jego zastosowanie jako leku

Country Status (36)

Country Link
US (2) US20050234104A1 (fr)
EP (2) EP1660482B1 (fr)
JP (2) JP5348842B2 (fr)
KR (1) KR101331039B1 (fr)
CN (2) CN1845917B (fr)
AR (2) AR045520A1 (fr)
AT (2) ATE529420T1 (fr)
AU (2) AU2004274139B2 (fr)
BR (1) BRPI0413849A (fr)
CA (2) CA2749579C (fr)
CO (1) CO5660265A2 (fr)
CY (2) CY1109299T1 (fr)
DE (2) DE10339862A1 (fr)
DK (2) DK2060569T3 (fr)
EA (1) EA009736B1 (fr)
EC (2) ECSP066399A (fr)
ES (2) ES2375896T3 (fr)
HK (2) HK1157760A1 (fr)
HR (2) HRP20090311T1 (fr)
IL (1) IL173885A (fr)
ME (1) ME00340B (fr)
MX (1) MXPA06001959A (fr)
MY (2) MY145696A (fr)
NO (2) NO334115B1 (fr)
NZ (2) NZ578586A (fr)
PE (1) PE20050348A1 (fr)
PL (2) PL2060569T3 (fr)
PT (2) PT1660482E (fr)
RS (2) RS20060136A (fr)
SG (1) SG145734A1 (fr)
SI (2) SI1660482T1 (fr)
TW (2) TWI418553B (fr)
UA (1) UA85686C2 (fr)
UY (2) UY28493A1 (fr)
WO (1) WO2005028468A1 (fr)
ZA (1) ZA200600518B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) * 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102006054005A1 (de) * 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
US20110129538A1 (en) * 2008-03-28 2011-06-02 Boehringer Ingelheim International Gmbh Process for preparing orally administered dabigatran formulations
AU2009272796A1 (en) 2008-07-14 2010-01-21 Boehringer Ingelheim International Gmbh Method for manufacturing medicinal compounds containing dabigatran
JP2012500243A (ja) * 2008-08-19 2012-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺高血圧症患者の治療のためのダビガトランエテキシラートの使用
JP2013510072A (ja) 2008-11-11 2013-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法
US20120142703A1 (en) 2009-05-14 2012-06-07 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
HUP1000069A2 (en) 2010-02-02 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag New salts for the preparation of pharmaceutical composition
US20130052262A1 (en) * 2010-03-01 2013-02-28 Sandra Brueck Dabigatran etexilate-containing oral pharmaceutical composition
US20130149346A1 (en) 2010-03-08 2013-06-13 ratiopharm GmbH Graf-Arco-Strasse 3 Dabigatran etexilate-containing pharmaceutical composition
US20130177652A1 (en) 2010-07-01 2013-07-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
WO2012027543A1 (fr) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Formes solides de dabigatran étexilate et de dabigatran étexilate mésylate et leurs méthodes de préparation
PL2603503T3 (pl) 2010-09-27 2015-12-31 Ratiopharm Gmbh Sól bismesylanowa eteksylanu dabigatranu, postacie stałe i sposób ich otrzymywania
WO2012077136A2 (fr) * 2010-12-06 2012-06-14 Msn Laboratories Limited Procédé de préparation de dérivés de benzimidazole et de leurs sels
HUP1100244A2 (hu) 2011-05-11 2012-11-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Gyógyszeripari intermedierek és eljárás elõállításukra
JP2014517843A (ja) 2011-05-24 2014-07-24 テバ ファーマシューティカル インダストリーズ リミティド 医薬組成物用の圧縮コア
AU2012357956A1 (en) 2011-12-22 2014-05-22 Boehringer Ingelheim International Gmbh Immediate release multi unit pellet system
WO2013111163A2 (fr) 2012-01-20 2013-08-01 Cadila Healthcare Limited Procédé de préparation de dabigatran étéxilate mésylate et polymorphes d'intermédiaires de celui-ci
WO2013110567A1 (fr) 2012-01-24 2013-08-01 Boehringer Ingelheim International Gmbh Nouvelle formulation de dabigatran à administration par voie orale
RU2633482C2 (ru) 2012-02-21 2017-10-12 Лабораторьос Дель Др. Эстеве, С.А. Пероральные фармацевтические композиции дабигатрана этексилата
EP2631234A1 (fr) * 2012-02-23 2013-08-28 Esteve Química, S.A. Formes solides de mesylate d'étexilate de dabigatran et leurs procédés de préparation
WO2013144971A1 (fr) 2012-03-27 2013-10-03 Cadila Healthcare Limited Nouvelles formes solides de bisulfate et de mésylate d'étéxilate de dabigatran, et leurs procédés de préparation
US9273030B2 (en) 2012-04-02 2016-03-01 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and salts thereof
WO2014012880A1 (fr) * 2012-07-16 2014-01-23 Interquim, S.A. Procédé de préparation d'intermédiaires pour la synthèse d'étexilate de dabigatran, et formes cristallines de ces intermédiaires
WO2014033693A1 (fr) 2012-08-31 2014-03-06 Ranbaxy Laboratories Limited Procédé de préparation de la forme cristalline i du sel méthanesulfonate d'étéxilate de dabigatran
CN103664882A (zh) * 2012-09-20 2014-03-26 天津药物研究院 结晶变体形态的达比加群酯及其制备方法和用途
CN103864756B (zh) * 2012-12-11 2018-06-15 四川海思科制药有限公司 丁二磺酸达比加群酯及其制备方法和用途
EP2835370A1 (fr) 2013-08-08 2015-02-11 Medichem, S.A. Nouveaux cristaux de dabigatran etexilate mésilate
CN104418840A (zh) * 2013-09-05 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯无水化合物
WO2015128875A2 (fr) 2014-02-26 2015-09-03 Megafine Pharma (P) Ltd. Procédé de préparation de dabigatran étéxilate mésylate et de ses intermédiaires
CN104892574A (zh) * 2014-03-04 2015-09-09 浙江海正药业股份有限公司 达比加群酯甲磺酸盐的晶型及其制备方法和用途
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
CN108947966A (zh) * 2014-04-04 2018-12-07 江苏天士力帝益药业有限公司 达比加群酯甲磺酸盐新晶型及其制备方法
CN105461686A (zh) * 2014-08-25 2016-04-06 江苏豪森药业股份有限公司 制备高纯度甲磺酸达比加群酯晶型的方法
CN104825422B (zh) * 2014-09-29 2017-12-12 普济生物科技（台州）有限公司 含达比加群酯甲磺酸盐的药物组合物及其制备方法
JP6581197B2 (ja) 2014-12-31 2019-09-25 深▲セン▼市薬欣生物科技有限公司Ｓｈｅｎｚｈｅｎ Ｐｈａｒｍａｃｉｎ Ｃｏ．， Ｌｔｄ． 医薬組成物及びその製造方法
CN104725360A (zh) * 2015-04-09 2015-06-24 重庆东得医药科技有限公司 一种甲磺酸达比加群酯ⅰ晶型的制备方法
WO2017111637A1 (fr) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Composition pharmaceutique comprenant du dabigatran ou un sel pharmaceutiquement acceptable de celui-ci
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN107778291A (zh) * 2016-08-31 2018-03-09 亚宝药业集团股份有限公司 一种甲磺酸达比加群酯晶型ⅱ的制备方法
CN116813691B (zh) 2018-10-29 2024-04-12 丽珠医药集团股份有限公司 新的二肽类化合物及其用途
JP2020193184A (ja) * 2019-05-30 2020-12-03 ダイト株式会社 ダビガトランエテキシラートメタンスルホン酸塩の形態ｉの製造方法
EP3771465A1 (fr) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Composition pharmaceutique comprenant du dabigatran etexilate
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN114380793B (zh) * 2020-10-20 2024-02-23 北京澳合药物研究院有限公司 一种甲磺酸达比加群酯晶型i的制备方法及其应用
US11446286B1 (en) * 2022-02-28 2022-09-20 King Faisal University Treatment of fungal infections using dabigatran etexilate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US4427468A (en) * 1976-01-16 1984-01-24 Her Majesty The Queen In Right Of Canada Curable propellant binding systems with bonding agent combination
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
US4675405A (en) * 1984-09-21 1987-06-23 American Home Products Corporation Quinoline compounds as antiallergic and antithrombotic agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5416099A (en) * 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
ATE217188T1 (de) * 1992-08-05 2002-05-15 Faulding F H & Co Ltd Granulierte pharmazeutische zusammensetzung
JPH06340619A (ja) 1993-05-03 1994-12-13 Bristol Myers Squibb Co グアニジニルまたはアミジニル置換メチルアミノ複素環トロンビン抑制剤
CA2134192A1 (fr) 1993-11-12 1995-05-13 Michael L. Denney Antagonistes iib/iiia de la glycoproteine 5, 6-bicyclique
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19752843C2 (de) 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
DE10133786A1 (de) 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
ATE540943T1 (de) * 2002-03-07 2012-01-15 Boehringer Ingelheim Pharma 3-ä(2-ää4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoümethylü-1-methyl-1h-benzimidazol-5- carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester methansulfonat
DE10245624A1 (de) * 2002-09-30 2004-04-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2004093881A2 (fr) * 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Utilisation du dipyridamole ou du mopidamole pour le traitement et la prevention de maladies thrombo-emboliques et de troubles induits par la formation excessive de thrombine et/ou par l'expression elevee des recepteurs de la thrombine
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
US20050107438A1 (en) * 2003-09-03 2005-05-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
EP1609784A1 (fr) * 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Procédé pour la préparation de 4-(benzimidazolylméthylamino)-benzamidines
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) * 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen

Also Published As

Publication number Publication date
UA85686C2 (ru) 2009-02-25
IL173885A0 (en) 2006-07-05
CN1845917B (zh) 2011-05-11
CA2537054A1 (fr) 2005-03-31
US7932273B2 (en) 2011-04-26
CA2749579A1 (fr) 2005-03-31
DK1660482T3 (da) 2009-08-24
SG145734A1 (en) 2008-09-29
JP2011178803A (ja) 2011-09-15
NZ578586A (en) 2011-01-28
AU2010201457A1 (en) 2010-05-06
CN102167695B (zh) 2013-06-19
ATE430145T1 (de) 2009-05-15
AR073225A2 (es) 2010-10-20
JP2007504106A (ja) 2007-03-01
BRPI0413849A (pt) 2006-10-24
JP5566332B2 (ja) 2014-08-06
JP5348842B2 (ja) 2013-11-20
PL1660482T3 (pl) 2009-08-31
MY145632A (en) 2012-03-15
RS53370B (en) 2014-10-31
PT2060569E (pt) 2011-12-29
DE502004009431D1 (en) 2009-06-10
AU2010201457B2 (en) 2012-05-10
IL173885A (en) 2015-04-30
ES2375896T3 (es) 2012-03-07
KR101331039B1 (ko) 2013-11-20
HK1096682A1 (fr) 2007-06-08
US20080119523A1 (en) 2008-05-22
DK2060569T3 (da) 2012-01-23
NZ545984A (en) 2009-08-28
EA200600381A1 (ru) 2006-08-25
CY1109299T1 (el) 2014-07-02
HK1157760A1 (en) 2012-07-06
NO20130778L (no) 2006-03-28
ATE529420T1 (de) 2011-11-15
PE20050348A1 (es) 2005-06-15
WO2005028468A1 (fr) 2005-03-31
KR20070031830A (ko) 2007-03-20
EP1660482B1 (fr) 2009-04-29
ES2326654T3 (es) 2009-10-16
RS20060136A (en) 2008-06-05
TWI375674B (en) 2012-11-01
MXPA06001959A (es) 2006-05-17
DE10339862A1 (de) 2005-03-24
UY28493A1 (es) 2005-03-31
TWI418553B (zh) 2013-12-11
EP2060569A1 (fr) 2009-05-20
MY145696A (en) 2012-03-30
CN1845917A (zh) 2006-10-11
CN102167695A (zh) 2011-08-31
HRP20090311T1 (en) 2009-07-31
AR045520A1 (es) 2005-11-02
TW201202217A (en) 2012-01-16
EP2060569B1 (fr) 2011-10-19
US20050234104A1 (en) 2005-10-20
SI1660482T1 (sl) 2009-10-31
SI2060569T1 (sl) 2012-01-31
AU2004274139A1 (en) 2005-03-31
ECSP11006399A (es) 2011-12-30
ECSP066399A (es) 2006-09-18
CA2749579C (fr) 2013-04-16
HRP20120028T1 (hr) 2012-01-31
ZA200600518B (en) 2006-12-27
EP1660482A1 (fr) 2006-05-31
TW200512206A (en) 2005-04-01
UY32342A (es) 2011-07-29
PT1660482E (pt) 2009-06-04
CY1112222T1 (el) 2015-12-09
MEP50608A (en) 2011-02-10
NO334115B1 (no) 2013-12-16
ME00340B (fr) 2011-05-10
CO5660265A2 (es) 2006-07-31
AU2004274139B2 (en) 2010-05-13
NO20061420L (no) 2006-03-28
EA009736B1 (ru) 2008-02-28
CA2537054C (fr) 2011-12-06

Similar Documents

Publication Publication Date Title
PL2060569T3 (pl) Hemihydrat metanosulfonianu estru etylowego kwasu 3-[(2-{[4-heksylokarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionowego i jego zastosowanie jako leku
EP1838633A4 (fr) Materiaux refractaires
EP1793892A4 (fr) Stimulateur gastrique receptif
EP1829271A4 (fr) Technique pour communiquer de facon securisee un contenu de programmation
PL370517A1 (en) Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h
HK1106557A1 (en) Susceptor
EP1968510A4 (fr) Bande gastrique à autorégulation
IL181674A0 (en) Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
EP1782832A4 (fr) Remède contre le diabète
EP1781127A4 (fr) Substrat a bande amelioree et bande provenant de celui-ci
EP1781133A4 (fr) Fermeture a glissiere
IL160858A (en) Nano-pesticide pesticide preparation and process for preparation
EP1732111A4 (fr) Suscepteur
TWI365725B (en) A bottom end stop for a slide fastener, and a slide fastener comprising such a bottom end stop
EP1753400A4 (fr) Forme de dosage de ziprasidone
ZA200903981B (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy-3-bromo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethyl-benzamide
PL1705998T3 (pl) Zastosowanie karboksypeptydazy
AU2003255890A8 (en) Nitrofurantoin controlled release dosage form
EP1753423A4 (fr) Benzo-urees a activite antidiabetique
GB0412185D0 (en) Lining product for buildings
GB2414535B (en) Programmer
IL180999A0 (en) Azo compounds and process for production thereof
GB2420336B (en) Infusion package
GB0410122D0 (en) Nursing poncho
GB0422353D0 (en) Naso gastric introducer